Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

ImmuPharma passes landmark as phase III dosing starts

In all clinical trials will take place across 45 locations – 10 in America, the rest in Europe.
ImmuPharma passes landmark as phase III dosing starts
Clinical trials are now under way on Lupuzor.

---ADDS CHAIRMAN COMMENTS---

ImmuPharma (LON:IMM) has begun dosing patients as part of the phase III clinical trial of its lead drug candidate Lupuzor for the life-threatening autoimmune disease Lupus.

This is a major milestone for the company, which has the chance to take the compound from discovery right the way through to the market.

Patients will receive the treatment at the US sites opened last December.

In all trials will take place across 45 locations – 10 in America, the rest in Europe.

A “delighted” ImmuPharma chairman Tim McCarthy told investors: “With recruitment going to plan, we look forward to providing further positive updates on this Lupuzor phase-III study as it progresses throughout this year and 2017.”

Lupuzor has "blockbuster" potential, which means, under the pharma industry's own definition, a drug that could generate US$1bn or more a year in revenue, so it's probably worth looking now at what Lupus is and who is affected by it.

Systemic Lupus Erythematosus (SLE) is a debilitating and painful disease, which sees the body's immune system turn against itself for reasons still not fully understood.

It can affect various organs in various people in various ways so many symptoms can ensue, which calls for treatment from heart, liver and skin specialists.

It is much more common in women, appears most often in African-Americans, Asians and Hispanics and it is estimated that up to five million individuals worldwide may be affected.

The company does not claim Lupuzor is a cure but it hopes it will offer significant relief to sufferers such that their quality of life is greatly improved.

It is also thought to work better than other products available, such as Glaxo's Benlysta, as it interacts with the body in a "different way" and at a "higher level" and also offers fewer side-effects.

In all, 200 Lupus sufferers will be brought on board at least by the end of 2016, and the aim is to complete the phase III trial by the end of 2017. Then the commercialisation process and all-important sales start coming into view.

Chairman McCarthy told Proactive Investors the European sites will be “opened in the next few weeks”, although the formal announcement will be made to the market.

“The fact we are on schedule is very good news,” he added.

Earlier this month the company said it was raising £8.3mln and investors will meet next week to sign off the package. The new shares will begin trading on February 25.

Before that - on Thursday (Feb 18) - investors will have the opportunity to catch up with chairman McCarthy at Proactive’s One2One Forum at Chesterfield Hotel, In London’s Mayfair.

For more information click this link.

 

View full IMM profile View Profile

ImmuPharma PLC Timeline

Related Articles

Woman with tissue facing pollen
October 20 2017
Allergy, which saw its market share grow by a percentage point to 13%, is in a strong financial position, with £22.1mln in the bank
scientist looking through a microscope
October 31 2017
As of March, ReNeuron had £53mln in cash equivalents but its market value is not too much above that....
test tubes filled with blood
November 02 2017
In all, 116 of the 200 patients with the life-threatening auto-immune disease have been through the 52-week process looking at the efficacy of Lupuzor

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use